北美疱疹市场 – 行业趋势和 2028 年预测

市场分析和洞察：北美疱疹市场

预计北美疱疹市场将在 2021 年至 2028 年的预测期内实现显着增长。Data Bridge Market Research 分析称，在 2021 年至 2028 年的预测期内，该市场的复合年增长率为 7.5%，预计将从 2020 年的 4.5334 亿美元增至 2028 年的 7.7417 亿美元。疱疹感染患病率的上升和老年人口的增加是主要驱动因素，预计这将推动预测期内市场的增长。

越来越多的人受到单纯疱疹病毒的影响，这需要高效、先进的抗疱疹治疗，以最大限度地降低治疗期间的风险。医疗保健系统在治疗患者时需要针对多种不同类型的疱疹的先进药物。因此，主要市场参与者高度关注产品发布和产品批准。此外，政府和监管机构通过产品批准为市场参与者提供支持。

疱疹疾病的发病率不断上升，各地区医疗支出不断增加，加速了医疗机构对抗疱疹药物的需求，从而推动了北美疱疹市场的增长。此外，老年人口的激增也进一步推动了市场的增长。然而，预计抗疱疹药物的高成本和产品召回将在预测期内阻碍市场增长。另一方面，市场参与者的战略举措和抗疱疹药物制造商数量的激增为该市场提供了机遇，预计将推动市场增长。然而，新冠肺炎期间疱疹药物和注射剂供应链中断以及制药行业劳动力短缺是该市场面临的主要挑战。

The North America herpes market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.   

The North America herpes market Scope and Market Size

The North America herpes market is segmented on the basis of virus type, product, drug type, age, route of administration, distribution channel, and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of virus type, the North America herpes market is segmented into herpes simplex and herpes zoster. In 2021, herpes simplex segment is expected to dominate the market due to rise in herpes infections and STD awareness in the region.  
• On the basis of product, the North America herpes market is segmented into acyclovir, docosanol, valacyclovir, famciclovir, and others. In 2021, acyclovir segment is expected to dominate the market because of growing awareness among people and rising healthcare expenditure, which has led to increased sales of this product.
• On the basis of drug type, the North America herpes market is segmented into prescription drug and over-the-counter drug. In 2021, prescription drug segment is expected to dominate the market as it suppresses herpes recurrences by 70%–80%.
• On the basis of age, the North America herpes market is segmented into adult and pediatrics. In 2021, adult segment is expected to dominate the market owing to rising geriatric population due to increasing life expectancy of people.
• On the basis of route of administration, the North America herpes market is segmented into topical, oral, and parenteral. In 2021, topical segment is expected to dominate the market as it speeds up the healing and decreases symptoms.
• On the basis of distribution channel, the North America herpes market is segmented into hospitals pharmacies, retail pharmacies, drug stores, online pharmacies, and others. In 2021, hospital pharmacies segment is expected to dominate the market owing to several major players in the market.
• On the basis of end users, the North America herpes market is segmented into hospital, speciality clinics, and others. In 2021, hospitals segment is expected to dominate the market due to growing awareness among people about herpes treatment.

North America Herpes Market Country Level Analysis

The North America herpes market is analyzed and market size information is provided based on virus type, product, drug type, age, route of administration, distribution channel, and end users. Countries covered in the North America herpes market report are the U.S., Canada, and Mexico.

North America is expected to dominate the North America herpes market due to increasing prevalence of herpes in the region. The U.S. is dominating the market and leading the growth in the North America herpes market due to rising herpes infections in the country.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Rising healthcare expenditure and high prevalence of herpes infections in the North America are creating new opportunities for players in the North America herpes market

Herpes simplex segment in the U.S. is expected to grow with the highest rate and it is dominating the North America region in the forecast period of 2021 to 2028 because of rising prevalence of herpes infections.

North America herpes market also provides you with detailed market analysis for every country growth in particular industry with the North America herpes market sales, impact of advancement in the North America herpes market and changes in regulatory scenarios with their support for the North America herpes market. The data is available for historic period 2010 to 2018. 

Competitive Landscape and North America herpes market Share Analysis

North America herpes market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to North America herpes market.

报告中涉及的主要参与者包括 Abbott、Apotex、Inc.、Avet Pharmaceuticals、Inc.、Bausch Health Companies、Inc. Cipla、Inc.、Dr. Reddy's Laboratories Ltd.、EPI Health、Fresenius Kabi AG、GlaxoSmithKline plc.、Glenmark Pharmaceutical Inc.、USA、Maruho Co.,Ltd.、Mylan NV、Pfizer Inc.、Sun Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Ltd.、Zydus Pharmaceuticals、Inc.、RECORDATI SpA、Aurobindo Pharma、Amneal Pharmaceuticals LLC、Slavia Pharm SRL 和 Blistex、Inc.，以及其他国内和北美参与者。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。

全球各地的公司也推出了许多产品并达成了多项协议，进一步加速了北美疱疹市场的增长。

例如，

• 2019 年 11 月，Mylan NV 宣布与辉瑞旗下 Upjohn 部门合作，新成立的公司名为 Viatris。两家公司合并成立新公司，扩大了其产品组合，从而增加了市场对其产品的需求。
• 2018 年 9 月，Avet Pharmaceuticals Inc. 宣布立即推出 200 毫克阿昔洛韦胶囊。此次发布增强了 Avet 广泛的仿制口服固体产品组合。该公司推出的这款新药增加了其在市场上的销量，从而增加了未来的收入。

SKU-64371